About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR

About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Disclosure to Stock Exchange
  - Annual Reports

 Annual Report 2019

Annual Report 2018

  - Biocon's Journey of Fortitude
  - Biocon Profile
  - CMD Profile
  - Video Gallery

  Biocon Academy


  Facilities Virtual Tour

Biocon Malaysia


Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon was among the early movers in industry to pursue a high risk strategy of developing biosimilars for global markets. Through our ‘Made in India’ biosimilars business, we seek to pursue a humanitarian path that will provide affordable access to high quality generic biologics to make a difference to diabetes, cancer and autoimmune diseases. We have succeeded in bringing the benefit of high quality biosimilars to patients in India, other emerging market countries in Latin America, Africa, Middle East & Turkey, Asia-Pacfic regions and also now in developed markets of U.S., EU and Japan.

A combination of specialized talent, state-of-the-art research and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global biopharmaceuticals player.



Biocon Performance Highlights of Q1FY20 by Kiran Mazumdar-Shaw, CMD, Biocon Ltd.

Biocon Corporate Overview
Stock Update

Company Announcements


Feb 22, 2020 
Company Statement: Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection

Feb 20, 2020 
Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019

Jan 23, 2020 
Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6%

Jan 20, 2020 
Company Statement: Biocon's Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA lnspection with Zero Observations

  Media Coverage  

Jan 8, 2020:
Biocon optimistic about hitting $1 billion in revenue by FY22 on back of new launches

Dec 11, 2019:
Biocon, partner Mylan launch oncology biosimilar trastuzumab in US

Nov 28, 2019:
USFDA nod to Biocon's new Bengaluru unit

Nov 28, 2019:
Biocon, Mylan get nod for pegfilgrastim drug







Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved